Objective: Premutation and intermediate CGG repeat length at the fragile X mental retardation 1 (FMR1) locus have been associated with premature ovarian failure. We tested whether intermediate length is associated with indicators of ovarian age in a sample of fertile women. Our primary measures of ovarian age were antimüllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels.
C GG repeat length at the fragile X mental retardation 1 (FMR1) locus is related to premature ovarian failure (POF) and possibly to other manifestations of accelerated ovarian aging. FMR1, a gene on the X chromosome that underlies the fragile X mental retardation syndrome, codes for a heterogeneous nuclear ribonucleoprotein (FMRP) that shuttles between the nucleus and the cytoplasm of neuronal cells. FMRP plays a subtle but critical role in the translation of messenger RNA (mRNA). The 5 ¶ untranslated region of the FMR1 gene has a polymorphic CGG repeat. Individuals with lengths of approximately 55 to 200 are considered premutation carriers because repeats of this length have a propensity to expand to the full mutation in the subsequent generation. 1 Premutation carriers are at increased risk for POF, usually defined as menopause before age 40 years or two elevated levels of follicle-stimulating hormone (FSH) 1 month apart. Several studies (reviewed by Wittenberger et al, 2 Sullivan et al, 3 and Karimov et al 4 ) showed associations, among women treated for infertility, with other indicators of premature ovarian aging, including menopause before age 45 years, elevated FSH levels, and decreased antimüllerian hormone (AMH) levels. Most studies 5<10 supported an association of CGG length with POF; risk ratios ranged from 5.8 to infinity. Among POF women with normal karyotypes, 2% to 10% are premutation carriers 7,9<11 compared with less than 1% of the general population.
The most probable mechanism for an association between CGG length and POF is that FMR1 mRNA has a toxic gain of function, leading to accelerated follicular atresia and, consequently, a smaller follicular pool at any given age. 3, 12, 13 This mechanism may be relevant to associations of intermediate length with POF. In males with intermediate length (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) , increased mRNA transcriptional activity was reported, 14 suggesting RNA Bgain-of-function[ toxicity even for larger normal alleles.
Some studies suggested that the association of length with POF is also present among women with lengths in the intermediate range (41-58, 8 35-54, 15 and 43-53 9 ; reviewed by Kline et al 16 ). Odds ratios (ORs) range from 2.4 to 5.5. A study in England 10 was interpreted to show no association with intermediate length. We disagree with this interpretation because POF cases and controls were analyzed differently: each case contributed two chromosomes to the analysis, whereas each control contributed only one chromosome. The published data were not sufficiently detailed to limit the analysis to one chromosome per case to compare with one chromosome per control. However, assuming that cases contributed one intermediatelength allele each, we estimate ORs of 1.8 for lengths 35 to 54 and 2.6 for lengths 41 to 58.
If the association of intermediate length with POF is causal, we expect intermediate length to be also associated with indicators (specifically low AMH and high FSH levels) of advanced ovarian age. AMH, which is expressed by granulosa cells, is detectable in some primary and secondary follicles and in most preantral and small (G6 mm) antral follicles. 17, 18 FSH, a gonadotropin under the negative feedback of inhibin B and estradiol, 19, 20 reflects the quantity or quality of antral follicles; it may also provide an indirect measure of the characteristics of the underlying oocyte pool. 21, 22 In a sample of 42 ovaries, 23 the age-adjusted correlation of ln(number of primordial follicles) with serum AMH level was stronger than the correlation with serum FSH level, suggesting that AMH level is the better indicator of the size of the oocyte pool. Data from two sites, analyzed together, 24 showed no association of intermediate length (n = 49; defined as 35-45 or 46-55) with decreased AMH levels.
We drew on data from fertile women (unselected for a family history of fragile X disorders) to test whether intermediate CGG length is associated with AMH or FSH levels. We also assessed associations with inhibin B and estradiol.
METHODS
Analyses draw on data from two studies (New York and New Jersey) designed to test whether indicators of ovarian age or possible causes of a decreased oocyte pool are associated with trisomic spontaneous abortions (SAs). The design and protocols of the two studies are similar. Both samples include women with karyotyped SAs and women with chromosomally normal live births (LBs). Previous analyses indicate that (1) trisomic SA is associated with elevated FSH levels, but not with changes in AMH, inhibin B, or estradiol levels 25 ; (2) trisomic SA is unrelated to highly skewed X inactivation 26 ; and (3) trisomic SA is unrelated to intermediate CGG length. 16 
New York study
The New York study 25, 27 was designed to test the hypothesis that the oocyte pools of women with trisomic pregnancies are smaller than those of women with pregnancies of other types.
From 1998 to 2001, we ascertained a consecutive series of SAs in one hospital. We attempted to karyotype all singleton prefetal (developmental age G9 wk) SAs to women 18 years or older. If a woman's loss was successfully karyotyped, we asked her to complete a short telephone interview to determine her eligibility for hormone studies. The principal exclusion criteria were use of hormonal contraceptives, pregnancy (SAs), or breast-feeding (LBs). Blood was collected on days 1 to 4 of each woman's second or later menstrual cycle.
Women with trisomic SAs constituted the case group. Women with nontrisomic chromosomally abnormal SAs and chromosomally normal SAs constituted two of the comparison groups; women with LBs constituted the third group. For each case who completed the study, we selected an age-matched (T6 mo) control with a chromosomally and anatomically normal LB of 1,800 g or higher during the 7 to 13 months before selection, no pregnancy loss since the index pregnancy, and no known trisomic pregnancy. Table S1a (Supplemental Digital Content 1, http://links.lww.com/MENO/A82) sets out the number of women identified and their eligibility for the present analysis.
New Jersey study
The New Jersey study 26 was designed to examine the relation of highly skewed X-chromosome inactivation to trisomy. We collected sera in anticipation of analyses to examine the relation of hormonal indicators of ovarian age to trisomy. 25 From 2003 to 2005, we ascertained a consecutive series of SAs in one hospital. The New Jersey study differed from the New York study in the following ways: (i) it included women with singleton SAs less than 18 weeks (rather than G9 wk) in developmental age; (ii) it included women ineligible for hormone measures (hormones were irrelevant to the primary aim); (iii) age-matched women with LBs were selected for all women with SAs (rather than only for women with trisomic SAs); (iv) we drew blood on days 2 to 4 (rather than on days 1-4); (v) in the event that a woman with an SA was eligible for hormone studies but her first LB control was not, we enrolled a second LB control who was eligible for hormone studies; and (vi) LB controls delivered 6 to 12 months (rather than 7-13 mo) preceding the date of their selection. Table S1b (Supplemental Digital Content 2, http://links.lww.com/MENO/A83) sets out the number of women identified and their eligibility for the present analysis.
Study of repeat structure
At the conclusion of the analyses reported here, we selected five matched pairs from the New Jersey study to examine the relation of the length of the longest uninterrupted CGG repeat to hormone level. (We selected women from the New Jersey study because we have more stored DNA from the New Jersey participants.) From among the 72 women with allele 2 intermediate repeat length (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) , we selected cases with Bolder ovarian age[Vthe five cases with the lowest AMH levels (0.071-0.187 ng/mL). Each AMH value was less than the 5th percentile for the woman's 5-year age group. Although not a selection criterion, all women had FSH levels in the upper 5th percentile for their 5-year age groups.
From the remaining 67 women with allele 2 intermediate repeat length, we sought five matched controls with Byounger ovarian age.[ We eliminated potential controls with allele 1 of intermediate length (n = 2) because no case had an allele 1 of intermediate length. We also eliminated women with AMH levels of 7.08 ng/mL or higher (n = 5) to exclude possible undetected cases of polycystic ovary syndrome. Among the remaining 60 women, we defined as potential controls women with (for their 5-y age group) (1) AMH levels equal to or greater than the median and (2) FSH levels less than the 75th percentile. Twenty-five women met these criteria for Byounger ovarian age.[ From these 25 women, we selected five controls matched as closely as possible to each case for allele 2 repeat length and age (Table 5, footnote).
Both studies
Each study was approved by the institutional review boards of the study hospital and of our institution. Mean maternal age is younger for the New York sample ( Table 1 ). Most women were white non-Hispanic. The distribution of CGG length, classified into five categories based on the length of allele 2, did not differ between sites; 14.9% had intermediate-length repeats. The proportion of LBs differs between sites because we selected LB controls for all SAs in the New Jersey study but only for trisomic SAs in the New York study.
Hormonal indicators of ovarian age
Blood samples were processed in a refrigerated centrifuge. After separation, sera were frozen at j25-C (New York) or j20-C (New Jersey) in the study hospital before delivery to New York City, where they were stored at j20-C. AMH and inhibin B levels were measured by enzyme-linked immunosorbent assays (DSL Inc, Webster, TX). FSH and estradiol levels were measured by solid-phase chemiluminescent enzyme immunoassays (Immulite; Diagnostic Products Co, Los Angeles, CA). For AMH, the sensitivity was 0.05 ng/mL, and the intraassay and interassay coefficients of variation were 2.3% and 8.9%, respectively. For FSH, the sensitivity was 0.1 mIU/mL, and the intra-assay and interassay coefficients of variation were 1.9% and 5.0%, respectively. For inhibin B, the sensitivity was 15 pg/mL, and the intra-assay and interassay coefficients of variation were 3.9% and 6.1%, respectively. For estradiol, the sensitivity was 20 pg/mL, and the intra-assay and interassay coefficients of variation were 9.3% and 10.5%, respectively.
Among all women with hormone measures, 25 chronologic age is inversely related to ln(AMH), positively related to ln(FSH) and ln(estradiol), and unrelated to ln(inhibin B). The correlation with estradiol is compatible with observations that levels may be elevated during the menopausal transition. 28, 29 FMR1 CGG repeat length
We previously described our measures of CGG length. 16 Length was determined by polymerase chain reaction (PCR) and capillary electrophoresis 30 using prototype FMR1 PCR reagents obtained from Asuragen Inc. Length was measured using Peak Scanner software after a comparison of PCR product length to a ladder of 5-carboxy-X-rhodamine (ROX)labeled size standards. All assay runs included a pooled mixture of five alleles ranging from 20 to 120 CGG repeats for which length had been previously verified by sequencing. We used these process controls to estimate length in the sample.
Randomly ordered samples were run in 30 batches. We estimated length from batch-specific linear regression equations relating the mobility of peaks from capillary electrophoresis analysis to the true length of process controls. The computation yields a noninteger estimate of length; we rounded these values to the nearest integer for analysis. A second DNA sample from five matched pairs was submitted for analysis of the structure of the CGG repeat. We used three PCR assays to identify the presence and location of interrupting AGG The proportion of white non-Hispanic women is significantly higher (P = 0.02) in the New York sample.
c
The distribution of CGG repeat length did not vary significantly (P = 0.81) between sites.
d
The lower proportion of live birth controls in the New York sample reflects the differing study designs: in New York, live birth controls were selected for trisomy cases only, whereas in New Jersey, live birth controls were selected for all women with losses.
sequences on each allele. 31 Uninterrupted CGG length was defined as the number of CGG repeats after the last AGG, if present, on that allele. All laboratory staff were blind to participant characteristics. We defined CGG length in three ways: length on allele 1, length on allele 2, and biallelic mean. In accordance with the predominant approach in the POF literature, 8 we consider length on allele 2 as the primary measure. Figure S1 (Supplemental Digital Content 3, http://links.lww.com/MENO/A84) shows the distribution of length for alleles 1 and 2. We analyzed each of the four measures as a categorical variable defined, approximately, by percentiles (lower 5th, 5th to G25th, 25th to G75th, 75th to G95th, upper 5th) among LB controls. We defined the middle category as the reference group. The upper 5th percentile for allele 2 ranged from 35 to 54 repeats. (Analyses excluded six women with premutations.) For the biallelic mean, the lower bound of the upper 5th percentile was 35.5. Because one study 32 suggested that FMRP expression is low for short alleles, we examined associations with short length on allele 1; the lower 5th percentile for allele 1 ranged from 9 to 19 repeats.
Statistical analyses
First, we used site-stratified multiple linear regression models to test the null hypothesis that intermediate CGG length is associated with any hormone. All analyses adjusted for karyotype group, age at blood draw, day of blood draw, duration of time in storage, and smoking history ( Table 3 ). We adjusted for these covariates because each was associated (P G 0.05) independently with one or more hormones in at least one sample. We estimated the magnitude of the associations between each category of length and hormone and set 95% CIs around the estimates. We used a logarithmic transformation for each hormone to meet the normal error assumption of leastsquares regression. Thus, differences correspond approximately to percent change in hormone level. To facilitate interpretation, we present the geometric means of hormone levels. The geometric mean corresponds to the median when the logarithmic hormone values have a symmetrical distribution, as they do in our data. The estimated percent change in median hormone level is equal to exp(difference) j 1. We combined the evidence from the two sites, weighting the regression coefficients by the inverse of their squared standard errors. We repeated the analyses (1) limiting the sample to LBs and (2) limiting the sample to white non-Hispanic women.
Second, we examined associations (for each site separately) of CGG length, defined by the length on allele 2 (Q35 vs 20-34), with hormones defined categorically. For AMH and inhibin B, we dichotomized as closely as possible to the 5th percentile among LBs to define older ovarian age (AMH e0.186 ng/mL and inhibin B e15 pg/mL). For FSH, we dichotomized at 10 mIU/mL or higher, a level (for the Immulite assay) used by several studies 33<35 to define older ovarian age. This level corresponds to approximately the top 5% of LBs. For estradiol, where either high or low levels might indicate older ovarian age, we used three categories: 20 pg/mL or lower (limit of detection; ,11th percentile), 85 pg/mL or higher (95th percentile), and, as the reference group, higher than 20 pg/mL to less than 85 pg/mL. Because the number of women with hormone levels indicating Bolder[ ovarian age was small, we adjusted only for site to estimate ORs for the two sites combined (using Mantel-Haenszel statistics). Most women with low AMH (32 of 38) or high FSH (37 of 40) levels were 35 years or older. We repeated the analyses limiting the sample to women 35 years or older. For FSH, which is elevated among women with trisomic losses, we repeated the analysis adjusting also for karyotype group and age (continuous).
RESULTS

Hormones: continuous
Among women with allele 2 lengths of 35 to 54, compared with women with length 30, estimated ln(AMH) is increased by 0.065 units in the total sample and decreased by 0.135 units among LBs (Tables 2, 3 , Fig. 1 ). A length of 35 to 54 is associated with increases in ln(FSH) of 0.025 units (total sample) and 0.087 units (LBs). For the total sample, point estimates correspond to an estimated change in the median of approximately 7% for AMH and 3% for FSH. All point estimates are compatible with zero. A length of 35 to 54 is unrelated to inhibin B or estradiol. Results were unchanged when we limited the analyses to white non-Hispanic women (n = 516): the adjusted differences (95% CIs) were 0.132 (j0.13 to 0.39) for ln(AMH) and 0.003 (j0.10 to 0.10) for ln(FSH) (data not shown).
Similar analyses for the total sample show no significant associations between long biallelic mean or short allele 1 length and any hormone (data not shown). For short allele 1 length, in the total sample, the adjusted differences (95% CIs) were 0.162 (j0.28 to 0.60) for ln(AMH) and 0.077 (j0.09 to 0.25) for ln(FSH).
Hormones: categorical
The proportion of women with hormone levels indicative of older ovarian age did not vary significantly with length (Table 4 ). For the longest category versus the remainder, the ORs (adjusted for site) were 0.7 for low AMH and 0.4 for high FSH. Results were essentially unchanged when we limited analyses to LBs. When we repeated the analyses among women 35 years or older (n = 315), the site-adjusted ORs (95% CIs) relating the longest category to low AMH and high FSH levels were 0.5 (0.1 to 2.2) and 0.4 (0.1 to 1.8). For FSH (which is associated with trisomy), adjusting also for karyotype and age (linear), the adjusted OR (95% CI) relating lengths 35 to 54 to elevated FSH was 0.6 (0.2 to 2.0).
Repeat structure
The CGG repeat was interrupted by AGG repeats in all instances; only one woman (a control) showed an uninterrupted repeat in the intermediate range ( Table 5 ). The mean length of the longest uninterrupted CGG repeat was significantly longer among women with younger ovarian age than among women with older ovarian age.
DISCUSSION
Our data do not support an association of intermediate CGG repeat length at the FMR1 locus with two indicators of ovarian aging. For allele 2 lengths 35 to 54, estimated changes in median AMH and FSH are approximately 7% and 3%, respectively. Our data rule out decreases in median AMH of 17% or more and increases in median FSH of 13% or more. When we categorized hormone level, intermediate length was unrelated to either low AMH (OR, 0.7) or high FSH (OR, 0.4). a Data from each site were analyzed separately. Within each site, analyses were adjusted for karyotype group (trisomy, other loss vs live birth), age in single years (linear and quadratic), smoking (former, current vs never), day of blood draw (days 1-2 vs days 3-4), and interval (continuous) between blood draw and assay. Age is associated with all four hormones; trisomy and current smoking are associated with elevated FSH; day of blood draw is associated with inhibin B and estradiol; and increasing interval in storage is associated with FSH and estradiol. For the sites combined, the adjusted difference in mean ln(hormone) is a weighted average of the difference for each site, weighting the site-specific estimated regression coefficient by the inverse of its squared standard error. b 95% CIs exclude a difference of zero in ln(hormone). Given the number of comparisons carried out, these two associations probably reflect type I error.
c In our sample, the longest CGG repeat length on allele 2 is 53.
Our data rule out associations of 1.8-fold or higher for AMH and 1.4-fold or higher for FSH. Results were essentially unchanged when we limited analyses to LBs, limited analyses to white non-Hispanic women, or defined length by the biallelic mean. Statistical power (0.80; > = 0.05, two-tailed) was sufficient to detect a 30% decrease in median AMH and a 15% increase in median FSH. For AMH and FSH defined categorically, detectable ORs are 3.2 and 3.0. Short (9-19) length on allele 1 is unrelated to either hormone. Decreases in median AMH of 24% or more are improbable.
We examined the structure of the CGG repeat to test whether our null result derives from misclassification (ie, our measure of CGG length did not take AGG interruptions into account). Contrary to our hypothesis, cases (older ovarian age) did not show longer uninterrupted CGG length. On the contrary, the uninterrupted repeat was significantly longer among controls (probably because of type I error). In all instances, the repeat was interrupted by AGG sequences, a result consistent with a previous observation. 31 The strengths of our study include the following: excellent assay validity and reliability, blinding of laboratory technicians to all characteristics of the women, random ordering of samples to prevent potential confounding by assay batch, a sample unselected for history of fragile X syndrome, and face validity.
The unselected sample allows us to generalize our findings to most women rather than only to women from families in which the premutation has demonstrated the capacity to expand; this is important because one study 36 indicated that the risk of expansion of lengths 55 to 59 to the full mutation in a single generation is lower for unselected women than for women from fragile X families. On the other hand, because our sample overrepresents SAs, findings might not be generalizable to all fertile women. To address this issue, we repeated all analyses limiting the sample to LBs. The findings for LBs are consistent with the findings for the total sample.
With respect to face validity, our rates of premutation are comparable to those observed in other samples 37<43 of women unselected for a family history of fragile X syndrome or developmental problems. Our rate of repeat length higher than 40 is similar to the rate observed in a survey 8 of 2,781 unselected women. 8 In contrast, two studies 9,10 of POF that defined intermediate length as 41 to 58 reported lower rates among controls.
For intermediate (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) length, our sample is larger than all but one reported series. Our rate of intermediate length (14.8%) is higher than those observed in most other studies. In a study 10 of POF, the untransmitted X was analyzed among 2,779 women who were screened because their sons had learning difficulties; 8.0% had intermediate length. Among smaller samples of fertile or unselected controls from one other study 15 of POF, two studies 44, 45 of occult POF among infertile women, and one study 42 of an unselected sample, rates of intermediate length ranged from 6.2% 42 to 13.0% 15 (our computations). (All studies, except one, 10 which analyzed only one chromosome per control, reported rates for alleles rather than for women. To estimate the above rates, we assumed that no woman had two alleles with intermediate length.) Disagreement between studies may reflect ethnic variation, small sample size, or different assays. Our data suggest that the proportion of women with intermediate length among a predominantly white non-Hispanic sample is higher than reported in most prior studies.
To our knowledge, our study is the first to assess the association between intermediate length and FSH in a sample unselected for infertility. With respect to AMH, our data are consistent with the one other study 24 in which women were not selected for infertility. In infertility treatment settings, several studies raise the possibility that intermediate length is associated with occult POF, for which elevated FSH is among the criteria. These data are difficult to interpret: (1) elevated basal FSH is only one of several criteria defining occult POF 4, 44, 46 ; (2) small samples limit statistical power 45 ; and (3) samples referred for FMR1 testing are vulnerable to potential selection bias. 44 We anticipated that AMH, because of its stronger correlation with the size of the primordial pool, 23 would measure ovarian age better than would FSH. The upper 95% confidence limits for low AMH and high FSH levels were 1.8 and 1.4, respectively. We thus reject the hypothesis that risk ratios for AMH or FSH are within the range (our computations, 1.8-5.5) reported for intermediate length in relation to POF. We consider four explanations:
1. Observations linking intermediate length to POF are in error. We note two methodologic issues of concern. (a) Except for one study, 15 rates of intermediate (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) length among controls from studies of POF 10 or occult POF 44, 45 are about half the rate observed in our sample. Although these variations may reflect true differences among samples, they may also reflect differences in assays; in case of the latter, the potential for misclassification limits inference. (b) It is unclear whether samples from cases and controls were assayed in the same batches. Our study, which randomly ordered samples for assays, eliminates the potential for confounding by technical differences between batches. 2. A one-time hormone measure may be insufficient to estimate ovarian age. Evidence of cycle-to-cycle variability stems mainly from studies of infertile women. No study of women unselected for infertility has used interclass correlation coefficients to evaluate variability, hindering their interpretability. For AMH, one study 47 showed similar means for two cycles. For follicular-phase FSH, two studies 47, 48 showed similar means for two cycles; two others 49, 50 indicated that variability may be greater for older women than for younger women. Three series supported the 55, 56 Among women with lengths 41 to 58, 9 the CGG repeat was uninterrupted in nine POF cases but interrupted with AGG repeats in two controls. In contrast, in our sample, the CGG repeat was interrupted in all 10 women studied.
CONCLUSIONS Most women with intermediate CGG repeat length are not at increased risk for accelerated ovarian aging. The discordance of this finding from findings related to POF suggests that the structure of the repeat determines its potential to affect the ovary. We favor efforts to determine whether the association between intermediate length on the FMR1 gene and POF is limited to repeats with particular structures or patterns. carried out the hormone assays; Karen Oppenheimer, who collaborated in the design of the CGG repeat length laboratory analyses, carried out the assays, and collaborated in their interpretation; and Judy Chih-Yu, who prepared the DNA. We thank Gary Latham (Asuragen Inc) for providing the reagents for this study and Stela Filipovic-Sadic and Eliot Blatt for performing the analyses related to repeat structure.
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